Meropenem NEW
| Price | $42 | $58 |
| Package | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Meropenem | CAS No.: 96036-03-2 |
| Purity: 99.71% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Meropenem |
| Description | Meropenem (SM 7338) is a synthetic carbapenem antibiotic with broad-spectrum antibacterial activity. It exerts a bactericidal effect by inhibiting the synthesis of peptidoglycan in the bacterial cell wall and is active against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria. Meropenem is active against both susceptible and resistant Neisseria gonorrhoeae (MIC values of 0.02–0.06 mg/mL), Haemophilus influenzae (MIC: 0.03–0.12 mg/mL), and Klebsiella pneumoniae (MIC: 0.015–0.12 mg/mL). Meropenem can be used for constructing bacterial infection models and screening for antimicrobial activity. |
| Kinase Assay | Complementation of SCR7 Inhibition with Puri?ed Ligase IV: Complementation experiment is carried out by adding increasing concentrations of puri?ed Ligase IV/XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5' compatible and 5'-5' noncompatible ends) to the SCR7-treatedextracts. Reactions are incubated for 2 h at 25℃. The reaction products are then resolved on 8% denaturing PAGE. The gel is dried and exposed and the signal is detected with a PhosphorImager and analyzed with Multi Gauge (V3.0) software. |
| In vitro | Methods: Clinical isolates of NDM-1-producing Escherichia coli ZC-YN3, along with strains producing NDM-5 and NDM-9, were tested against monotherapy with Meropenem or Magnolol, or combination therapy with Meropenem + Magnolol (32 μg/mL) to determine the minimum inhibitory concentration (MIC). Results: Meropenem monotherapy MIC: 16 μg/mL (against ZC-YN3); Magnolol monotherapy MIC: >1024 μg/mL (no direct antibacterial activity); Meropenem + Magnolol combination MIC: 4 μg/mL (against ZC-YN3), representing a 4-fold reduction. [1] Methods: Human primary alveolar epithelial cells (HPAEpiC) were infected with PAO1 strain after mechanical stretching simulated by the FlexCell system. Drugs (meropenem at 5×MIC and 0.5×MIC) were added 2 hours post-infection. Bacterial load was assessed at 4 and 8 hours post-infection. Results: Meropenem effectively reduced bacterial load. [2] |
| In vivo | Methods: C57BL/6J mice were mechanically ventilated and infected with PAO1 strain via tracheal inoculation. Meropenem monotherapy was administered via intraperitoneal injection at 4 hours and 16 hours post-infection. Results: Meropenem monotherapy significantly reduced bacterial load in both the lungs and systemic tissues [2]. |
| Storage | Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (10.43 mM), Sonication is recommended. DMSO : 100 mg/mL (260.78 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : 5 mg/mL (13.04 mM), Sonication is recommended. |
| Keywords | β-lactamases | β-Lactamase | SM-7338 | SM7338 | parenteral | neutropenia | Meropenem | Inhibitor | inhibit | Gram-positive | Gram-negative | DHP-1 | D-alanyl-D-alanine carboxypeptidase DacB | carbapenem | Bacterial | Antibiotic | anaerobic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | EMA Approved Drug Library | Drug Repurposing Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library | NMPA-Approved Drug Library | Human Metabolite Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-27 | ||
| $990.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-07-27 | |
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-27 | ||
|
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2026-07-23 | ||
| $8.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-09 | |
| $58.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $58.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $30.00 |
VIP6Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2026-05-28 | |
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1.00 |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2026-02-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY